Latest research on Aripiprazole

Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.

Aripiprazole side effects

After 2 months of Aripiprazole treatment, no side effects were noted and the patient stated that most of her vesicles had disappeared. [source, 2015]
Aripiprazole is a relatively new drug that by some patients is tolerated better than other atypical antipsychotics because it gives less metabolic side effects (weight gain, dyslipidemia and diabetes mellitus; Citrome et al., 2014). [source, 2015]
Data on individual AP drugs are more controversial, with individual phenothiazines and butyrophenones (e.g., Haloperidol) carrying a higher risk as compared with some individual second-generation AP drugs, such as Quetiapine and Olanzapine, which may have a moderate risk, or Aripiprazole, possibly showing a lower potential to cause QTc prolongation [3;4]. [source, 2016]
Side effects of Aripiprazole included significant increase in mean body weight, body mass index, and waist circumference. [source, 2016]
This proportion could also be increased with the recent appearance of new second-generation LAIAs, such as Olanzapine pamoate, PP, and Aripiprazole depot.49 [source, 2015]
Because of its partial antagonistic activity on Dopamine D2 receptors, Aripiprazole is associated with an especially low risk of developing tardive dystonia. [source, 2015]
Nonetheless, Aripiprazole has also been shown to cause tardive dystonia in some cases, and motor symptoms of Aripiprazole-induced tardive dystonia can sometimes be reversed by withdrawal of Aripiprazole and addition of anticholinergic medications [10–13]. [source, 2015]
However, the patient and his family refused to take more than 5-mg Aripiprazole because of a concern of adverse events by dose escalation. [source, 2015]
Aripiprazole was continued for about 6 months even after the onset of dystonia, because he and his family refused to change medication because of fear of adverse events by new medication. [source, 2015]
Because his dystonia became worse as time progressed we decided to discontinue Aripiprazole. [source, 2015]